Alto Neuroscience Announces Topline Data From Phase 2 POC Clinical Trial Evaluating ALTO-101 For Treatment Of CIAS; ALTO-101 Did Not Achieve Statistical Significance On Primary EEG Or Cognitive Endpoints Versus Placebo

Alto Neuroscience, Inc. (NYSE: ANRO) announced that its Phase 2 proof-of-concept trial for ALTO-101 in treating cognitive impairment associated with schizophrenia did not achieve statistical significance on primary EEG or cognitive endpoints compared to placebo. However, the study showed near-significant improvement in theta-ITC (p=0.052) and nominally significant effects in a more cognitively impaired subgroup (p=0.03). The company plans to prioritize its lead program, ALTO-207, while exploring partnership opportunities for a modified-release formulation of ALTO-101, which has shown improved pharmacokinetics and tolerability. Further data from the study is expected to be presented at a future medical conference.